Connect with us

Coronavirus (Covid-19)

Questions raised over AstraZeneca “dosing mistake” in vaccine trials

Published

 on 

British-Swedish pharmaceutical company AstraZeneca announced this week that their experimental coronavirus vaccine candidate is, on average, 70% effective. But since Monday’s announcement vaccine experts from around the world have questioned the methodology of the trials and transparency of the announced Phase 3 trial results.

The questions and uncertainty of the AstraZeneca vaccine trials will set back the timing for the vaccine to be authorised other parts of the world. Scientists are curious why the company has pooled results from  different trials, saying that this “deviates from standard reporting on clinical trials”.

AstraZeneca announced last Monday that the participants in the UK had been given 2 different courses of the candidate vaccine.

The drugmaker, who co-developed the vaccine with the University of Oxford, didn’t explain why they used 2 different dosing regimens, or why the size of one group was significantly smaller than the other.

• In one group, 2,741 participants received a half-dose of the vaccine followed by a full dose at least 30 days later. This group was 90% protected against Covid-19.

• In the second group, 8,895 participants received a full dose followed by another full dose a month later. This group was only 62% protected.

The 2 trials, when averaged, according to AstraZeneca, gives their vaccine its reported 70% effectiveness. But epidemiologists say that the small number of people in the low dose group make it difficult to know if the effectiveness “was a statistical quirk”.

David Salisbury, from the global health program at London-based Chatham House, said another area of confusion was that the studies pooled results from the two groups to reach an average of 70% efficacy. Speaking to AP…

“You’ve taken two studies for which different doses were used and come up with a composite that doesn’t represent either of the doses. I think many people are having trouble with that.″

Then, Mene Pangalos, head of biopharmaceuticals research and development at AstraZeneca, responded to Reuters saying that a “lab error” was the reason why some volunteers had received a smaller dose… the dose that proved to be 90% effective.

“The reason we had the half dose is serendipity, Researchers had underpredicted the dose of the vaccine by half.”

Then, the next day, University of Oxford chimed in in a statement… “dose selection for any new vaccine is a complicated area, and in exploring methods of dose selection, we discovered one gave a lower dose than expected.”

“A difference in the manufacturing process had led to the error.”

AstraZeneca say that these “manufacturing problems” have been corrected, noting that the UK regulator overseeing the trial had agreed to include “both approaches” in Phase 3.

Speaking to the Wall Street Journal on Wednesday, Menelas Pangalos said that the mistake is actually irrelevant.

“Whichever way you cut the data, even if you only believe the full-dose, full-dose data, we still have efficacy that meets the thresholds for approval with a vaccine that’s over 60% effective.”

The trial’s lead investigator at Oxford University, Professor Andrew Pollard, as part of the announcements on Monday, said that’s the issue is likely to do with the delicate balance of dosing someone just enough to trigger an immune response against the disease.

“What we’ve always tried to do with a vaccine is fool the immune system into thinking that there’s a dangerous infection there that it needs to respond to, but doing it in a very safe way.”

“So, it may be that the best way of kicking the immune system into action could be to give the body a small amount of the vaccine to begin with, and then follow up with a larger amount.”

Responding to whether he had genuine confidence that the half-dose group’s 90% success was not just a feature of a small sample size, Pollard said that result was “highly significant…even with the numbers that we have.”

Moncef Slaoui, a US-based researcher and former head of GlaxoSmithKline’s vaccines department who leads the US coronavirus vaccine program, says they were reviewing AstraZeneca’s vaccine data.

He noted that group that got the lower dose that yielded the 90% efficacy had been a younger group, with no one older than 55.

“That could potentially affect the strength of AstraZeneca’s findings, given that young people typically produce stronger immune responses to vaccines. We want it to be based on data and science.”

Natalie Dean, assistant professor of biostatistics at the University of Florida said that the AstraZeneca/Oxford University team “get a poor grade for transparency and rigour when it comes to the vaccine trial results”.

“This is not like Pfizer or Moderna where we had the protocols in advance and a pre-specified primary analysis was reported.”

AstraZeneca shares have fallen 12% since November 11.

SOURCE: Euro News | Reuters | CNN

 

Get more from The Thaiger

Join the conversation and have your say on Thailand news published on The Thaiger.

Thaiger Talk is our new Thaiger Community where you can join the discussion on everything happening in Thailand right now.

Please note that articles are not posted to the forum instantly and can take up to 20 min before being visible. Click for more information and the Thaiger Talk Guidelines.

The Thaiger is Thailand's largest online portal for news, videos and information.

Follow Thaiger by email:

Visa9 hours ago

CCSA to consider extending Thailand tourist visa to 45 days

Bangkok9 hours ago

Man caught taking drugs inside a Bangkok police booth didn’t give a crap

Thailand9 hours ago

Thailand News Today | Thailand no longer considers Covid “dangerous infectious disease” 

Sponsored18 hours ago

Enjoy a splashing time and immerse yourself in Thai Mythology in Andamanda Phuket

Crime10 hours ago

Wife says boss of Mountain B in Pattaya is ‘not a villain’

Crime10 hours ago

Policeman poses as Buddhist monk to trick drug dealers in central Thailand

Travel10 hours ago

Stress-free travel with AXA Travel Insurance

Join the conversation on the Thaiger Talk forums today!
Guides10 hours ago

Mother’s Day in Thailand 2022: 5 fun ways to pamper your mom

Thailand10 hours ago

Thai minister insists minimum wage increase is not electioneering

Bangkok11 hours ago

Swedish Embassy hailed for giving 6-month parental leave to Thai staff

Travel12 hours ago

Everything you need to know about the Bangkok Skytrain (BTS)

Environment12 hours ago

PM warns Thailand to brace itself for potential flooding

Travel13 hours ago

Watch Koh Samui’s magical sunset from these sunset bars

Thailand13 hours ago

Local hero predicts building collapse, saves countless lives in eastern Thailand

Phuket13 hours ago

9 year old boy kills a 7 year old girl with a police pistol in Phuket

Press Room14 hours ago

Southeast Asia’s sauciest tech event, Techsauce Global Summit to return to Bangkok in physical form

Thailand11 months ago

Morning Top Stories Thailand | Police to end protests, Human Trafficking | September 14

Thailand1 year ago

Thailand News Today | Thai Airways in rehab, All go for Songkran | March 4

Tourism1 year ago

Phuket’s nightlife. Yes, bars and clubs are still open | VIDEO

Phuket1 year ago

Thailand News Today | Covid passport talks, Thai Airways heads to court | March 2

Tourism1 year ago

Phuket Thai food treats you need to try | VIDEO

Thailand1 year ago

Thailand News Today | Bars, pubs and restaurants ‘sort of’ back to normal | Feb 23

Tourism1 year ago

In search of Cat & Dog Cafés in Phuket Town | VIDEO

Thailand2 years ago

Thailand News Today | Gambling crackdown, Seafood market to reopen, Vlogger challenge | Jan 21

Thailand2 years ago

Thailand News Today | Covid testing for visas, Business impact, Vaccine approval | January 19

Thailand2 years ago

Thailand News Today | Weekend Bangkok bombs, Thailand fires, Covid update | January 18

Thailand2 years ago

Thailand News Today | Stray car on runway, Indonesian quake, 300 baht tourist fee | January 15

Thailand2 years ago

Thailand News Today | Governor off respirator, sex-trafficking arrest, condo prices falling | January 14

Thailand2 years ago

Thailand News Today | Chinese vaccine, Thailand ‘drug hub’, Covid update | January 13

Thailand2 years ago

Thailand News Today | Bangkok may ease restrictions, Phuket bar curfew, Vaccine roll out | January 12

Thailand2 years ago

Thailand News Today | Covid latest, Cockfights closed down, Bryde’s Whale beached | January 11

Trending